Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9Ovarian Neoplasms 8Breast Neoplasms 7Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumors 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasm Epithelial 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Gemcitabine 8Capecitabine 6pembrolizumab 5Carboplatin 5Pemetrexed 3Paclitaxel 3Oxaliplatin 3Irinotecan 3regorafenib 2osimertinib 2Taxes 2Sunitinib 2Radiotherapy 2Fluorouracil 2Cisplatin 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tislelizumab 1tegafur-gimeracil-oteracil 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1sintilimab 1seribantumab 1selinexor 1ruxolitinib 1rubitecan 1pralsetinib 1palbociclib 1olaparib 1niraparib 1linifanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma × olaparib × Clear all
NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

Phase 1/2 Terminated
19 enrolled 11 charts
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡